Transdermal Drug Delivery System is a medicated adhesive patch that is placed on the skin to deliver a specific dose of medication through the skin and into the bloodstream. Often, this promotes healing to an injured area of the body. An advantage of a transdermal drug delivery route over other types of medication delivery such as oral, topical, intravenous, intramuscular, etc. is that the patch provides a controlled release of the medication into the patient, usually through either a porous membrane covering a reservoir of medication or through body heat melting thin layers of medication embedded in the adhesive.
The global Transdermal Drug Delivery System market size was valued at US$ 17730 million in 2023 and is forecast to a readjusted size of USD 41310 million by 2030 with a CAGR of 13.0% during review period.
Global Transdermal Drug Delivery System key players include Hisamitsu, Mylan, GSK, Novartis, Teve (Actavis), etc. Global top five manufacturers hold a share over 65%. North America is the largest market, with a share over 40%, followed by Europe and Asia-Pacific, both have a share over 45% percent.
In terms of product, Nitroglycerin is the largest segment, with a share over 25%. And in terms of application, the largest application is OTC, followed by RX.
This report is a detailed and comprehensive analysis for global Transdermal Drug Delivery System market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.
Key Features:
Global Transdermal Drug Delivery System market size and forecasts, in consumption value ($ Million), 2019-2030
Global Transdermal Drug Delivery System market size and forecasts by region and country, in consumption value ($ Million), 2019-2030
Global Transdermal Drug Delivery System market size and forecasts, by Type and by Application, in consumption value ($ Million), 2019-2030
Global Transdermal Drug Delivery System market shares of main players, in revenue ($ Million), 2019-2024
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Transdermal Drug Delivery System
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Transdermal Drug Delivery System market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Hisamitsu, Mylan, GSK, Novartis, Teve (Actavis), Johnson & Johnson, Lohmann, Teikoku Seiyaku, Bayer, Lingrui, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
麻豆原创 segmentation
Transdermal Drug Delivery System market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segmentation
Transdermal Drug Delivery System market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segment by Type
Fentanyl
Nitroglycerin
Estradiol
Nicotine
Other
麻豆原创 segment by Application
OTC
Rx
麻豆原创 segment by players, this report covers
Hisamitsu
Mylan
GSK
Novartis
Teve (Actavis)
Johnson & Johnson
Lohmann
Teikoku Seiyaku
Bayer
Lingrui
Sanofi
Qizheng
Endo
Huarun 999
Haw Par
Nichiban
Mentholatum
Laboratoires Genevrier
麻豆原创 segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Transdermal Drug Delivery System product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Transdermal Drug Delivery System, with revenue, gross margin, and global market share of Transdermal Drug Delivery System from 2019 to 2024.
Chapter 3, the Transdermal Drug Delivery System competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Transdermal Drug Delivery System market forecast, by regions, by Type and by Application, with consumption value, from 2024 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Transdermal Drug Delivery System.
Chapter 13, to describe Transdermal Drug Delivery System research findings and conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.
1 麻豆原创 Overview
1.1 Product Overview and Scope
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 Classification of Transdermal Drug Delivery System by Type
1.3.1 Overview: Global Transdermal Drug Delivery System 麻豆原创 Size by Type: 2019 Versus 2023 Versus 2030
1.3.2 Global Transdermal Drug Delivery System Consumption Value 麻豆原创 Share by Type in 2023
1.3.3 Fentanyl
1.3.4 Nitroglycerin
1.3.5 Estradiol
1.3.6 Nicotine
1.3.7 Other
1.4 Global Transdermal Drug Delivery System 麻豆原创 by Application
1.4.1 Overview: Global Transdermal Drug Delivery System 麻豆原创 Size by Application: 2019 Versus 2023 Versus 2030
1.4.2 OTC
1.4.3 Rx
1.5 Global Transdermal Drug Delivery System 麻豆原创 Size & Forecast
1.6 Global Transdermal Drug Delivery System 麻豆原创 Size and Forecast by Region
1.6.1 Global Transdermal Drug Delivery System 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
1.6.2 Global Transdermal Drug Delivery System 麻豆原创 Size by Region, (2019-2030)
1.6.3 North America Transdermal Drug Delivery System 麻豆原创 Size and Prospect (2019-2030)
1.6.4 Europe Transdermal Drug Delivery System 麻豆原创 Size and Prospect (2019-2030)
1.6.5 Asia-Pacific Transdermal Drug Delivery System 麻豆原创 Size and Prospect (2019-2030)
1.6.6 South America Transdermal Drug Delivery System 麻豆原创 Size and Prospect (2019-2030)
1.6.7 Middle East & Africa Transdermal Drug Delivery System 麻豆原创 Size and Prospect (2019-2030)
2 Company Profiles
2.1 Hisamitsu
2.1.1 Hisamitsu Details
2.1.2 Hisamitsu Major Business
2.1.3 Hisamitsu Transdermal Drug Delivery System Product and Solutions
2.1.4 Hisamitsu Transdermal Drug Delivery System Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.1.5 Hisamitsu Recent Developments and Future Plans
2.2 Mylan
2.2.1 Mylan Details
2.2.2 Mylan Major Business
2.2.3 Mylan Transdermal Drug Delivery System Product and Solutions
2.2.4 Mylan Transdermal Drug Delivery System Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.2.5 Mylan Recent Developments and Future Plans
2.3 GSK
2.3.1 GSK Details
2.3.2 GSK Major Business
2.3.3 GSK Transdermal Drug Delivery System Product and Solutions
2.3.4 GSK Transdermal Drug Delivery System Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.3.5 GSK Recent Developments and Future Plans
2.4 Novartis
2.4.1 Novartis Details
2.4.2 Novartis Major Business
2.4.3 Novartis Transdermal Drug Delivery System Product and Solutions
2.4.4 Novartis Transdermal Drug Delivery System Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.4.5 Novartis Recent Developments and Future Plans
2.5 Teve (Actavis)
2.5.1 Teve (Actavis) Details
2.5.2 Teve (Actavis) Major Business
2.5.3 Teve (Actavis) Transdermal Drug Delivery System Product and Solutions
2.5.4 Teve (Actavis) Transdermal Drug Delivery System Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.5.5 Teve (Actavis) Recent Developments and Future Plans
2.6 Johnson & Johnson
2.6.1 Johnson & Johnson Details
2.6.2 Johnson & Johnson Major Business
2.6.3 Johnson & Johnson Transdermal Drug Delivery System Product and Solutions
2.6.4 Johnson & Johnson Transdermal Drug Delivery System Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.6.5 Johnson & Johnson Recent Developments and Future Plans
2.7 Lohmann
2.7.1 Lohmann Details
2.7.2 Lohmann Major Business
2.7.3 Lohmann Transdermal Drug Delivery System Product and Solutions
2.7.4 Lohmann Transdermal Drug Delivery System Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.7.5 Lohmann Recent Developments and Future Plans
2.8 Teikoku Seiyaku
2.8.1 Teikoku Seiyaku Details
2.8.2 Teikoku Seiyaku Major Business
2.8.3 Teikoku Seiyaku Transdermal Drug Delivery System Product and Solutions
2.8.4 Teikoku Seiyaku Transdermal Drug Delivery System Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.8.5 Teikoku Seiyaku Recent Developments and Future Plans
2.9 Bayer
2.9.1 Bayer Details
2.9.2 Bayer Major Business
2.9.3 Bayer Transdermal Drug Delivery System Product and Solutions
2.9.4 Bayer Transdermal Drug Delivery System Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.9.5 Bayer Recent Developments and Future Plans
2.10 Lingrui
2.10.1 Lingrui Details
2.10.2 Lingrui Major Business
2.10.3 Lingrui Transdermal Drug Delivery System Product and Solutions
2.10.4 Lingrui Transdermal Drug Delivery System Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.10.5 Lingrui Recent Developments and Future Plans
2.11 Sanofi
2.11.1 Sanofi Details
2.11.2 Sanofi Major Business
2.11.3 Sanofi Transdermal Drug Delivery System Product and Solutions
2.11.4 Sanofi Transdermal Drug Delivery System Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.11.5 Sanofi Recent Developments and Future Plans
2.12 Qizheng
2.12.1 Qizheng Details
2.12.2 Qizheng Major Business
2.12.3 Qizheng Transdermal Drug Delivery System Product and Solutions
2.12.4 Qizheng Transdermal Drug Delivery System Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.12.5 Qizheng Recent Developments and Future Plans
2.13 Endo
2.13.1 Endo Details
2.13.2 Endo Major Business
2.13.3 Endo Transdermal Drug Delivery System Product and Solutions
2.13.4 Endo Transdermal Drug Delivery System Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.13.5 Endo Recent Developments and Future Plans
2.14 Huarun 999
2.14.1 Huarun 999 Details
2.14.2 Huarun 999 Major Business
2.14.3 Huarun 999 Transdermal Drug Delivery System Product and Solutions
2.14.4 Huarun 999 Transdermal Drug Delivery System Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.14.5 Huarun 999 Recent Developments and Future Plans
2.15 Haw Par
2.15.1 Haw Par Details
2.15.2 Haw Par Major Business
2.15.3 Haw Par Transdermal Drug Delivery System Product and Solutions
2.15.4 Haw Par Transdermal Drug Delivery System Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.15.5 Haw Par Recent Developments and Future Plans
2.16 Nichiban
2.16.1 Nichiban Details
2.16.2 Nichiban Major Business
2.16.3 Nichiban Transdermal Drug Delivery System Product and Solutions
2.16.4 Nichiban Transdermal Drug Delivery System Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.16.5 Nichiban Recent Developments and Future Plans
2.17 Mentholatum
2.17.1 Mentholatum Details
2.17.2 Mentholatum Major Business
2.17.3 Mentholatum Transdermal Drug Delivery System Product and Solutions
2.17.4 Mentholatum Transdermal Drug Delivery System Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.17.5 Mentholatum Recent Developments and Future Plans
2.18 Laboratoires Genevrier
2.18.1 Laboratoires Genevrier Details
2.18.2 Laboratoires Genevrier Major Business
2.18.3 Laboratoires Genevrier Transdermal Drug Delivery System Product and Solutions
2.18.4 Laboratoires Genevrier Transdermal Drug Delivery System Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.18.5 Laboratoires Genevrier Recent Developments and Future Plans
3 麻豆原创 Competition, by Players
3.1 Global Transdermal Drug Delivery System Revenue and Share by Players (2019-2024)
3.2 麻豆原创 Share Analysis (2023)
3.2.1 麻豆原创 Share of Transdermal Drug Delivery System by Company Revenue
3.2.2 Top 3 Transdermal Drug Delivery System Players 麻豆原创 Share in 2023
3.2.3 Top 6 Transdermal Drug Delivery System Players 麻豆原创 Share in 2023
3.3 Transdermal Drug Delivery System 麻豆原创: Overall Company Footprint Analysis
3.3.1 Transdermal Drug Delivery System 麻豆原创: Region Footprint
3.3.2 Transdermal Drug Delivery System 麻豆原创: Company Product Type Footprint
3.3.3 Transdermal Drug Delivery System 麻豆原创: Company Product Application Footprint
3.4 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 麻豆原创 Size Segment by Type
4.1 Global Transdermal Drug Delivery System Consumption Value and 麻豆原创 Share by Type (2019-2024)
4.2 Global Transdermal Drug Delivery System 麻豆原创 Forecast by Type (2025-2030)
5 麻豆原创 Size Segment by Application
5.1 Global Transdermal Drug Delivery System Consumption Value 麻豆原创 Share by Application (2019-2024)
5.2 Global Transdermal Drug Delivery System 麻豆原创 Forecast by Application (2025-2030)
6 North America
6.1 North America Transdermal Drug Delivery System Consumption Value by Type (2019-2030)
6.2 North America Transdermal Drug Delivery System 麻豆原创 Size by Application (2019-2030)
6.3 North America Transdermal Drug Delivery System 麻豆原创 Size by Country
6.3.1 North America Transdermal Drug Delivery System Consumption Value by Country (2019-2030)
6.3.2 United States Transdermal Drug Delivery System 麻豆原创 Size and Forecast (2019-2030)
6.3.3 Canada Transdermal Drug Delivery System 麻豆原创 Size and Forecast (2019-2030)
6.3.4 Mexico Transdermal Drug Delivery System 麻豆原创 Size and Forecast (2019-2030)
7 Europe
7.1 Europe Transdermal Drug Delivery System Consumption Value by Type (2019-2030)
7.2 Europe Transdermal Drug Delivery System Consumption Value by Application (2019-2030)
7.3 Europe Transdermal Drug Delivery System 麻豆原创 Size by Country
7.3.1 Europe Transdermal Drug Delivery System Consumption Value by Country (2019-2030)
7.3.2 Germany Transdermal Drug Delivery System 麻豆原创 Size and Forecast (2019-2030)
7.3.3 France Transdermal Drug Delivery System 麻豆原创 Size and Forecast (2019-2030)
7.3.4 United Kingdom Transdermal Drug Delivery System 麻豆原创 Size and Forecast (2019-2030)
7.3.5 Russia Transdermal Drug Delivery System 麻豆原创 Size and Forecast (2019-2030)
7.3.6 Italy Transdermal Drug Delivery System 麻豆原创 Size and Forecast (2019-2030)
8 Asia-Pacific
8.1 Asia-Pacific Transdermal Drug Delivery System Consumption Value by Type (2019-2030)
8.2 Asia-Pacific Transdermal Drug Delivery System Consumption Value by Application (2019-2030)
8.3 Asia-Pacific Transdermal Drug Delivery System 麻豆原创 Size by Region
8.3.1 Asia-Pacific Transdermal Drug Delivery System Consumption Value by Region (2019-2030)
8.3.2 China Transdermal Drug Delivery System 麻豆原创 Size and Forecast (2019-2030)
8.3.3 Japan Transdermal Drug Delivery System 麻豆原创 Size and Forecast (2019-2030)
8.3.4 South Korea Transdermal Drug Delivery System 麻豆原创 Size and Forecast (2019-2030)
8.3.5 India Transdermal Drug Delivery System 麻豆原创 Size and Forecast (2019-2030)
8.3.6 Southeast Asia Transdermal Drug Delivery System 麻豆原创 Size and Forecast (2019-2030)
8.3.7 Australia Transdermal Drug Delivery System 麻豆原创 Size and Forecast (2019-2030)
9 South America
9.1 South America Transdermal Drug Delivery System Consumption Value by Type (2019-2030)
9.2 South America Transdermal Drug Delivery System Consumption Value by Application (2019-2030)
9.3 South America Transdermal Drug Delivery System 麻豆原创 Size by Country
9.3.1 South America Transdermal Drug Delivery System Consumption Value by Country (2019-2030)
9.3.2 Brazil Transdermal Drug Delivery System 麻豆原创 Size and Forecast (2019-2030)
9.3.3 Argentina Transdermal Drug Delivery System 麻豆原创 Size and Forecast (2019-2030)
10 Middle East & Africa
10.1 Middle East & Africa Transdermal Drug Delivery System Consumption Value by Type (2019-2030)
10.2 Middle East & Africa Transdermal Drug Delivery System Consumption Value by Application (2019-2030)
10.3 Middle East & Africa Transdermal Drug Delivery System 麻豆原创 Size by Country
10.3.1 Middle East & Africa Transdermal Drug Delivery System Consumption Value by Country (2019-2030)
10.3.2 Turkey Transdermal Drug Delivery System 麻豆原创 Size and Forecast (2019-2030)
10.3.3 Saudi Arabia Transdermal Drug Delivery System 麻豆原创 Size and Forecast (2019-2030)
10.3.4 UAE Transdermal Drug Delivery System 麻豆原创 Size and Forecast (2019-2030)
11 麻豆原创 Dynamics
11.1 Transdermal Drug Delivery System 麻豆原创 Drivers
11.2 Transdermal Drug Delivery System 麻豆原创 Restraints
11.3 Transdermal Drug Delivery System Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Industry Chain Analysis
12.1 Transdermal Drug Delivery System Industry Chain
12.2 Transdermal Drug Delivery System Upstream Analysis
12.3 Transdermal Drug Delivery System Midstream Analysis
12.4 Transdermal Drug Delivery System Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Hisamitsu
Mylan
GSK
Novartis
Teve (Actavis)
Johnson & Johnson
Lohmann
Teikoku Seiyaku
Bayer
Lingrui
Sanofi
Qizheng
Endo
Huarun 999
Haw Par
Nichiban
Mentholatum
Laboratoires Genevrier
听
听
*If Applicable.
